Meproson

Methylprednisolone

Rheumatic disorders, skin infections/diseases. Tab: Bronchial asthma, allergic rhinitis, urticaria, eczema or dermatitis, hemolytic anemia, idiopathic thrombocytopenia, myeloblastosis, lymphogranulomatosis, ulcerative colitis, nephrotic syndrome, lupus erythematosus, dermatomyositis. Inj: Endocrine, collagen, allergic conditions, ophth, GI, resp diseases; haematological disorders, palliative treatment of leukemia & lymphoma in adults, acute leukemia in childn, terminal stage of cancer; edematous conditions; cerebral edema of primary tumor or metastatic conditions &/or related w/ surgery or RT, acute exacerbation of multiple sclerosis, acute trauma of spinal cord; meningitis TB w/ subarachnoidal block or impending block, trichinosis w/ neurologic & myocardial involvement.

Tab 4-48 mg daily. IV 30 mg/kg for 30 min, may be repeated every 4-6 hr for 48 hr.

Should be taken with food.

Hypersensitivity to methylprednisolone or other glucocorticoids. Systemic fungal infections. Intrathecal, epidural route. Live or live attenuated vaccines. Premature babies.

HTN & heart disease. Prolonged use may cause subcapsular cataract, glaucoma, ophth infection due to virus or fungi. Monitor blood glucose in diabetic patients. W/drawal of treatment should be performed gradually. Doses may be increased in patients in stress condition. Patients w/ latent TB or tuberculine reactivity. Patients w/ hypothyroidism or cirrhosis. Intrathecal or epidural route of administration. Not recommended in pregnancy & lactation. Prolonged use in childn.

Moon face, fat deposits, muscle weakness, HTN, osteoporosis, reduced glucose tolerance, DM, impaired sex hormone secretion, peptic ulcer, reduced body immune, growth retardation in childn, glaucoma, cataract, thrombosis, pancreatitis; headache, vertigo, convulsion, increased intracranial tension w/ papilledema; electrolyte & body fluid imbalance, dermatologic & immunologic disorders; euphoria, psychologic dependence, mood swing, depression, personality changes, insomnia, increased ICP w/ papilledema in childn (pseudotumor cerebri), psychosis, aggravated schizophrenia, seizure; leucocytosis, hypersensitivity reactions. Dizziness, visual disturbances, fatigue. Inj: Arachnoiditis, intestinal/bladder dysfunction, meningitis, paraparesis/paraplegia, sensory disorders.

Tab: Concomitant use w/ cardiac glycosides, diuretics, glucocorticoid, cyclosporine, ketoconazole, troleandomycin, rifampicin, rifabutin, carbamazepine, phenobarb, phenytoin, primidone, aminoglutethimide, NSAIDs, salicylate. Inj: Concomitant use w/ INH, rifampicin, oral anticoagulants, carbamazepine, phenobarb, phenytoin, neuromuscular blockers, anticholinesterase, antidiabetic agents, aprepitant, fosaprepitant, itraconazole, ketoconazole, HIV PIs (eg, indinavir, ritonavir), aminoglutethimide, diltiazem, ethinylestradiol/norethinderone, grapefruit juice, cyclophosphamide, tacrolimus, clarithromycin, erythromycin, troleandomycin, NSAIDs, high dose aspirin (ASA), K depleting agents (amphotericin B, xanthenes, β₂ agonists.

Corticosteroid Hormones

H02AB04 - methylprednisolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.

G